![]() |
Back |
Fibrocell to Present at 20th Annual Rodman & Renshaw Global Investment Conference |
A live webcast of Fibrocell’s presentation will be available under the investor relations section of the Company’s website at www.fibrocell.com/investors/events and archived for 30 days. About Fibrocell Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue. Fibrocell’s most advanced product candidate, FCX-007, is the subject of a Phase 1/2 clinical trial for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is also developing FCX-013, the Company’s product candidate for the treatment of moderate to severe localized scleroderma. Fibrocell’s gene therapy portfolio is being developed in collaboration with Trademarks Fibrocell®, the Fibrocell logo, and Investor & Media Relations Contact: |
![]() ![]() ![]() ![]() ![]() |